Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmanex files preemptive suit against FDA over Cholestin.

This article was originally published in The Tan Sheet

Executive Summary

PHARMANEX SEEKING COURT DECLARATION THAT CHOLESTIN CHOLESTEROL CLAIMS are acceptable under the Dietary Supplement Health & Education Act in a lawsuit filed against FDA in Salt Lake City, Utah federal court April 7. The company filed the suit after being informed by FDA in a meeting earlier the same day that the agency is interested in pursuing regulatory action against the product as an unapproved new drug. The suit is an attempt to preempt such action.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086922

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel